Skip to main content
. 2021 May 11;9(5):489. doi: 10.3390/vaccines9050489

Table 1.

SARS-CoV-2 vaccines that received EUA from the FDA.

Developer Type Doses Participants/P3 Study Location Efficacy/US EUA Date
Pfizer-BioNTech mRNA 2 43,548 International 95% 11 December 2020
Moderna-NIAID mRNA 2 34,420 United States 94% 18 December 2020
Johnson&Johnson-Janssen Viral vector 1 43,783 International 72% 27 February 2021

EUA (Emergency Use Authorization), NIAID (National Institute of Allergy and Infectious Diseases) P3 (Phase III clinical trials).